Isomorphic Labs Drug Design Engine Doubles AlphaFold 3 Accuracy, Heads to Clinical Trials

Isomorphic Labs Drug Design Engine Doubles AlphaFold 3 Accuracy, Heads to Clinical Trials

Isomorphic Labs, the drug discovery company founded by Google DeepMind CEO Demis Hassabis, released its Drug Design Engine (IsoDDE) in March 2026. The system doubles AlphaFold 3's accuracy when predicting protein-ligand structures that differ from training data.

How It Works

The Drug Design Engine identifies previously unknown docking sites on proteins in seconds with laboratory-grade precision. It estimates binding strength at a fraction of traditional costs. The system goes beyond structure prediction into full molecule design, targeting properties like selectivity, toxicity, and synthesizability.

Clinical Trials

Demis Hassabis announced at the World Economic Forum in Davos that the first AI-designed cancer drug from Isomorphic Labs is entering Phase 1 clinical trials in early 2026. Several additional lead candidates for oncology and immune-mediated disorders are in the IND-enabling phase.

Pharma Partnerships

Isomorphic Labs has strategic partnerships with Eli Lilly and Novartis. The deals are valued at nearly $3 billion in potential milestone payments. These are among the largest AI-pharma partnerships to date.

Why It Matters

Traditional drug discovery takes 10 to 15 years and costs over $1 billion per approved drug. AI-driven design compresses the early stages of this pipeline from years to months. If the clinical trials succeed, it would be the first time an AI-designed molecule reaches human patients through a major pharma partner, validating the approach for the entire industry.